KOD (Kodiak Sciences) 5-Year EBITDA Growth Rate: 1.40% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KOD Kodiak Sciences Inc KOD
26 GF Score
Price $37.64
! 3 Warning Signs
View Full Analysis

What is Kodiak Sciences 5-Year EBITDA Growth Rate?

Kodiak Sciences KOD -3.43% 26 5-Year EBITDA Growth Rate is 1.40% as of Jun. 2026. GuruFocus rates KOD with a GF Score™ of 26/100. The stock has 3 warning signs investors should review.

Kodiak Sciences's EBITDA per Share for the three months ended in Jun. 2026 was $-0.97.

During the past 3 years, the average EBITDA Per Share Growth Rate was 14.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 1.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kodiak Sciences was 17.10% per year. The lowest was -71.40% per year. And the median was -24.60% per year.

Kodiak Sciences  (NAS:KOD) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Kodiak Sciences 5-Year EBITDA Growth Rate Related Terms

KOD vs BEAM, TARS, VERA: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Kodiak Sciences's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kodiak Sciences 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kodiak Sciences's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Kodiak Sciences's 5-Year EBITDA Growth Rate falls into.


KOD
26GF Score
Kodiak Sciences Inc KOD
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kodiak Sciences 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 1.40% mean?
Kodiak Sciences (KOD) has a 5-Year EBITDA Growth Rate of 1.40% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Kodiak Sciences and its competitors.
Is Kodiak Sciences' 5-Year EBITDA Growth Rate too high?
Kodiak Sciences' current 5-Year EBITDA Growth Rate is 1.40%. Overall, Kodiak Sciences has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Kodiak Sciences' 5-Year EBITDA Growth Rate compare to BEAM and TARS?
Kodiak Sciences' 5-Year EBITDA Growth Rate of 1.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Kodiak Sciences and its competitors. Kodiak Sciences's current 5-Year EBITDA Growth Rate is 1.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kodiak Sciences stock overvalued right now?
Kodiak Sciences (KOD) has a current 5-Year EBITDA Growth Rate of 1.40%. The current 5-Year EBITDA Growth Rate is 1.40%. Kodiak Sciences' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Kodiak Sciences (KOD), the current 5-Year EBITDA Growth Rate is 1.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kodiak Sciences Business Description

Other Exchanges K27:Germany
Address 1250 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
26GF Score

Get the complete analysis for KOD

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.64
Price